Chinese study reports longer treatment window for stroke drug
Chinese medical scientists are reported to have developed Loberamisal, a drug intended to protect brain cells after a stroke. The study says it could extend the period for treatment from six hours to two days, although the supplied material does not provide its findings, trial details or regulatory status.
Chinese medical scientists have reported a drug that could extend the time available to treat damage caused by a stroke, according to the South China Morning Post. The drug, named Loberamisal, is described as protecting brain cells injured when a clot blocks an artery. The source says this could extend the treatment window from six hours to two days, potentially improving the prospects of recovery for some patients.
A stroke caused by a blocked artery can begin damaging brain cells within minutes. The source identifies facial drooping, impaired speech and, in severe cases, paralysis or death among the possible consequences. Existing emergency treatments mentioned in the report include clot-busting medicines and surgery.
These interventions must generally be delivered within a maximum period of six hours, according to the supplied material. The report refers to a study published by an unspecified publication, but the excerpt does not provide the study’s authors, number of participants, results or whether Loberamisal has received regulatory approval. It therefore does not establish when the drug could become available in clinical practice.
This independently written report is based on information supplied by the named publisher. Vertrix News has not independently verified the source report.